Literature DB >> 12700233

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.

Xiao-Feng Le1, Francois-Xavier Claret, Amy Lammayot, Ling Tian, Deepa Deshpande, Ruth LaPushin, Ana M Tari, Robert C Bast.   

Abstract

Cyclin-dependent kinase (CDK) inhibitor p27Kip1 binds to the cyclin E.CDK2 complex and plays a major role in controlling cell cycle and cell growth. Our group and others have reported that anti-HER2 monoclonal antibodies exert inhibitory effects on HER2-overexpressing breast cancers through G1 cell cycle arrest associated with induction of p27Kip1 and reduction of CDK2. The role of p27Kip1 in anti-HER2 antibody-induced cell cycle arrest and growth inhibition is, however, still uncertain. Here we have provided several lines of evidence supporting a critical role for p27Kip1 in the anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. Induction of p27Kip1 and G1 growth arrest by anti-HER2 antibody, murine 4D5, or humanized trastuzumab (Herceptin) are concentration-dependent, time-dependent, irreversible, and long-lasting. The magnitude of G1 cell cycle arrest induced by trastuzumab or 4D5 is well correlated with the level of p27Kip1 protein induced. Up-regulation of p27Kip1 and G1 growth arrest could no longer be removed with as little as 14 h of treatment with trastuzumab. Anti-HER2 antibody-induced p27Kip1 protein, G1 arrest, and growth inhibition persist at least 5 days after a single treatment. The magnitude of growth inhibition of breast cancer cells induced by anti-HER2 antibody closely parallels the level of p27Kip1 induced. Induced expression of exogenous p27Kip1 results in a p27Kip1 level-dependent G1 cell cycle arrest and growth inhibition similar to that obtained with anti-HER2 antibodies. Reducing p27Kip1 expression using p27Kip1 small interfering RNA blocks anti-HER2 antibody-induced p27Kip1 up-regulation and G1 arrest. Treatment with anti-HER2 antibody significantly increases the half-life of p27Kip1 protein. Inhibition of ubiquitin-proteasome pathway, but not inhibition of calpain and caspase activities, up-regulates p27Kip1 protein to a degree comparable with that obtained with anti-HER2 antibodies. We have further demonstrated that anti-HER2 antibody significantly decreases threonine phosphorylation of p27Kip1 protein at position 187 (Thr-187) and increases serine phosphorylation of p27Kip1 protein at position 10 (Ser-10). Expression of S10A and T187A mutant p27Kip1 protein increases the fraction of cells in G1 and reduces a further antibody-induced G1 arrest. Consequently, p27Kip1 plays an important role in the anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition through post-translational regulation. Regulation of the phosphorylation of p27Kip1 protein is one of the post-translational mechanisms by which anti-HER2 antibody upregulates the protein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700233     DOI: 10.1074/jbc.M300848200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

Review 1.  The interface between phosphatidylinositol transfer protein function and phosphoinositide signaling in higher eukaryotes.

Authors:  Aby Grabon; Vytas A Bankaitis; Mark I McDermott
Journal:  J Lipid Res       Date:  2018-11-30       Impact factor: 5.922

2.  The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Authors:  Xiao-Feng Le; Weiqun Mao; Guangan He; Francois-Xavier Claret; Weiya Xia; Ahmed Ashour Ahmed; Mien-Chie Hung; Zahid H Siddik; Robert C Bast
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

3.  IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance.

Authors:  Colin D White; Zhigang Li; Deborah A Dillon; David B Sacks
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

4.  Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Authors:  Martin Schwill; Rastislav Tamaskovic; Aaron S Gajadhar; Florian Kast; Forest M White; Andreas Plückthun
Journal:  Sci Signal       Date:  2019-01-22       Impact factor: 8.192

5.  Targeted deletion of Capn4 in cells of the chondrocyte lineage impairs chondrocyte proliferation and differentiation.

Authors:  Aki Kashiwagi; Ernestina Schipani; Mikaela J Fein; Peter A Greer; Masako Shimada
Journal:  Mol Cell Biol       Date:  2010-04-05       Impact factor: 4.272

6.  MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.

Authors:  Ajoy K Samanta; Helen J Huang; Xiao-Feng Le; Weiqun Mao; Karen H Lu; Robert C Bast; Warren S-L Liao
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

Review 7.  Role of trastuzumab in the management of HER2-positive metastatic breast cancer.

Authors:  Andrea Milani; Filippo Montemurro; Luisa Gioeni; Massimo Aglietta; Giorgio Valabrega
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-11-24

Review 8.  HER2-positive male breast cancer: an update.

Authors:  Laura Ottini; Carlo Capalbo; Piera Rizzolo; Valentina Silvestri; Giuseppe Bronte; Sergio Rizzo; Antonio Russo
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-10-04

Review 9.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

10.  Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.

Authors:  F Végran; R Boidot; B Coudert; P Fumoleau; L Arnould; J Garnier; S Causeret; J Fraise; D Dembélé; S Lizard-Nacol
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.